Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

s primarily due to increased employee expenses and increased costs associated with operating as a public company. The decrease for the nine month period in 2008 was due primarily to higher financing related costs incurred in 2007 attributable to OncoGenex Technologies' preparation for an initial public offering in the 2007 period, partly offset by higher employee expenses and increased costs associated with operating as a public company in the 2008 period.

Net income for the third quarter and nine months ended September 30, 2008, was $4.6 million and $0.8 million respectively, compared to net losses of $1.9 million and $6.3 million respectively in 2007. The net income recognized in both 2008 periods was primarily due to the impact of an extraordinary gain on the reverse takeover of Sonus and a reversal of tax expense associated with the change in capital structure of OncoGenex Technologies, both non-cash items.

The Company had $17.2 million in cash, cash equivalents and short-term investments as of September 30, 2008, compared with $5.1 million as of December 31, 2007. The Company has 5,513,643 shares outstanding as at November 7, 2008 of which 694,431 are subject to escrow provisions. OncoGenex continues to believe it has sufficient cash, cash equivalents and short-term investments to fund its currently planned operations through 2009, including:

- completion to final data of its ongoing Phase 2 clinical trials of

OGX-011;

- completion of its Phase 1 clinical trial of OGX-427;

- reaching an agreement with the U.S. Food and Drug Administration

(FDA) on the design of an additional Phase 3 registration trial of

OGX-011 in patients with hormone refractory prostate cancer via the

Special Protocol Assessment (SPA) process; and

- completion of pharmacology and formulation evaluations of CSP-9222.

"We have achieved important milestones in the third quarter of 2008 further
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Houston, Texas (PRWEB) March 26, 2015 ... assist technologies, and Transonic, a supplier of precision transit-time ... board that will greatly improve the efficiency of the ... will enable LVAD patients to experience greater mobility and ... embedded with the miniature flow board, will draw 1/6th ...
(Date:3/25/2015)... Agnition announced today that it will be ... for the first time at 7:30 a.m. CST March ... explore the extremely important role soil microbes perform in ... Microbial Catalyst™ technology that enhances soil and plant health ... air again on April 28. , A biochemist at ...
(Date:3/25/2015)... Vernon Hills, IL (PRWEB) March 25, 2015 ... new Cole-Parmer® Symmetry® Top-Loading Balances and Analytical Balances ... savvy. The expanded line of weighing balances from ... PT Precision Toploading Balances increase your efficiency ... of a variety of samples. Weighing modes include ...
(Date:3/25/2015)... San Francisco, CA (PRWEB) March 25, 2015 ... Provide Support for Novel Mechanism of Action in ... March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) ... its fast skeletal muscle troponin activator tirasemtiv in ... from a Phase IIa “Evidence of Effect” or ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... 11, 2010 Roche Diabetes Care, makers of ACCU-CHEK® ... World Diabetes Day (Nov. 14) through two truly ... (Photo: http://www.newscom.com/cgi-bin/prnh/20101111/DE99363 ) Roche Diabetes ... as a demonstration of support for people around the ...
... Berkeley, scientists have found a way to overcome one of ... of the picture. Everyone who has had an ultrasound, ... of the images. One of the limits to the detail ... basic laws of physics dictate that the smallest objects you ...
... produced at the Nano-Science Center, University of Copenhagen will ... high-efficiency solar cells and electronics on a nanometer scale. ... with a number of well-known researchers and the company ... have recently been published in the prestigious journal ...
Cached Biology Technology:Roche Diabetes Care Forms Human Blue Circle, Supports Viral Video for World Diabetes Day 2Roche Diabetes Care Forms Human Blue Circle, Supports Viral Video for World Diabetes Day 3Novel metamaterial vastly improves quality of ultrasound imaging 2New ultra-clean nanowires have great potential 2
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
(Date:3/18/2015)... CORAL SPRINGS, Florida , March 18, 2015 ... as well as businesses, new revolutionary smart wallets and apps ... rapid pace.  Companies currently entrenched in the mobile payment industry ... ), Alibaba Group Holding Ltd. (NYSE: BABA ), ... GOOG ) and Facebook Inc. (NASDAQ: ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... infectious diseases are urgently needed in resource-limited countries. ... Academy of Microbiology colloquium, "Bringing the Lab to ... Settings," describes the challenges inherent in bringing new ... the world where they are needed most. Point-of-care ...
... team of UC Davis investigators has found that a genetic ... prostate cancer. The mutation of the so-called p53 (or Tp53) ... now has never been shown to act as an initiating ... treating the disease. The study was published online ...
... one of the few probiotics with medical food designation for ... of more than 80 studies that have demonstrated its use ... ileal pouch. Ulcerative colitis patients, in particular, have been shown ... drug regimen. One particular study shows that the combination of ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
...
... undoubtedly the most complete and professional software ... layers and subsets makes it is possible ... data outputs, for example Cy3 and Cy5, ... as different subsets of genes and/or arrays. ...
...
Biology Products: